
LBRX Stock Forecast & Price Target
LBRX Analyst Ratings
Bulls say
LB Pharmaceuticals is well positioned for future growth with its novel LB-102 drug in late-stage clinical development for schizophrenia and bipolar depression. Its promising results, favorable safety profile, and potential market exclusivity make it a strong contender in the growing neuropsychiatry market. With a strong financial position and potential for partnership, the company is poised for success in bringing this much-needed drug to market.
Bears say
LB Pharmaceuticals is currently focused on developing LB-102, a drug for the treatment of neuropsychiatric disorders, particularly schizophrenia and bipolar depression. However, with a discounted cash flow-based valuation method and a relatively low probability of approval (POA) for LB-102, the company's prospects may be risky. In addition, the company has not yet been profitable and may not begin generating revenue until 2029. Without projected revenue in 2026 and 2027, the potential for long-term equity dilution and the challenging reimbursement landscape in the United States, the stock may have limited potential for growth.
This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
LBRX Analyst Forecast & Price Prediction
Start investing in LBRX
Order type
Buy in
Order amount
Est. shares
0 shares